These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 17660217

  • 1. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.
    Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A.
    Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217
    [Abstract] [Full Text] [Related]

  • 2. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 3. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis.
    Magnani A, Pistorio A, Magni-Manzoni S, Falcone A, Lombardini G, Bandeira M, Rossi F, Sala I, Martini A, Ravelli A.
    J Rheumatol; 2009 Mar; 36(3):628-34. PubMed ID: 19208600
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
    Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A, Pediatric Rheumatology International Trials Organization.
    Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
    [Abstract] [Full Text] [Related]

  • 5. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.
    Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MA, Hollingworth P, Cawkwell G, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organisation (PRINTO).
    Ann Rheum Dis; 2010 Aug; 69(8):1479-83. PubMed ID: 20525842
    [Abstract] [Full Text] [Related]

  • 6. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
    Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ.
    Arthritis Rheum; 2009 Jan 15; 61(1):46-51. PubMed ID: 19116975
    [Abstract] [Full Text] [Related]

  • 7. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F.
    J Rheumatol; 2009 Oct 15; 36(10):2308-13. PubMed ID: 19684155
    [Abstract] [Full Text] [Related]

  • 8. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.
    Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhães C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organization (PRINTO).
    Ann Rheum Dis; 2008 Mar 15; 67(3):309-14. PubMed ID: 17875547
    [Abstract] [Full Text] [Related]

  • 9. [Methotrexate treatment in refractory juvenile rheumatoid arthritis].
    Brik R.
    Harefuah; 1998 Dec 01; 135(11):509-11, 567. PubMed ID: 10911466
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May 01; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 11. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis.
    Foeldvari I, Wierk A.
    J Rheumatol; 2005 Feb 01; 32(2):362-5. PubMed ID: 15693100
    [Abstract] [Full Text] [Related]

  • 12. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
    Ringold S, Chon Y, Singer NG.
    Arthritis Rheum; 2009 Dec 01; 60(12):3776-83. PubMed ID: 19950286
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F.
    Arthritis Rheum; 2005 Feb 01; 52(2):548-53. PubMed ID: 15693004
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr 01; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 15. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2011 Sep 01; 70(9):1605-12. PubMed ID: 21623000
    [Abstract] [Full Text] [Related]

  • 16. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN.
    J Rheumatol; 2004 Jan 01; 31(1):179-82. PubMed ID: 14705239
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
    van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, ten Cate R, van Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, Oostveen JC, Kuis W, Dijkmans BA, Dutch Juvenile Idiopathic Arthritis Study group.
    Ann Rheum Dis; 2007 Nov 01; 66(11):1518-24. PubMed ID: 17491099
    [Abstract] [Full Text] [Related]

  • 18. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort.
    Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chédeville G, Chetaille AL, Saint-Cyr C, Cabral DA, Spiegel LR, Schneider R, Lang B, Huber AM, Dancey P, Silverman E, Rosenberg AM, Cameron B, Johnson N, Dorval J, Scuccimarri R, Campillo S, Petty RE, Duffy KN, Boire G, Haddad E, Houghton K, Laxer R, Turvey SE, Miettunen P, Gross K, Guzman J, Benseler S, Feldman BM, Espinosa V, Yeung RS, Tucker L.
    Arthritis Care Res (Hoboken); 2010 Apr 01; 62(4):527-36. PubMed ID: 20391508
    [Abstract] [Full Text] [Related]

  • 19. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis.
    Dolezalová P, Krijt J, Chládek J, Nemcová D, Hoza J.
    Rheumatology (Oxford); 2005 Jan 01; 44(1):74-9. PubMed ID: 15454631
    [Abstract] [Full Text] [Related]

  • 20. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis.
    Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A.
    J Rheumatol; 1995 Aug 01; 22(8):1574-6. PubMed ID: 7473486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.